DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Friday. The firm set a “hold” rating on the stock.

Other equities research analysts have also issued research reports about the company. HC Wainwright boosted their target price on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Down 5.5 %

DBV Technologies stock opened at $4.47 on Friday. The firm has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $3.84. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $9.49. The company has a market capitalization of $91.95 million, a PE ratio of -0.99 and a beta of 0.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.